Wnt signaling as a therapeutic target for bone diseases

Luke H. Hoeppner, Frank J. Secreto, Jennifer J Westendorf

Research output: Contribution to journalArticle

156 Citations (Scopus)

Abstract

Background: There is a need to develop new bone anabolic agents because current bone regeneration regimens have limitations. The Wingless-type MMTV integration site (Wnt) pathway has emerged as a regulator of bone formation and regeneration. Objective: To review the molecular basis for Wnt pathway modulation and discuss strategies that target it and improve bone mass. Methods: Data in peer-reviewed reports and meeting abstracts are discussed. Results/conclusions: Neutralizing inhibitors of Wnt signaling have emerged as promising strategies. Small-molecule inhibitors of glycogen synthase kinase 3? increase bone mass, lower adiposity and reduce fracture risk. Neutralizing antibodies to Dickkopf 1, secreted Frizzled-related protein 1 and sclerostin produce similar outcomes in animal models. These drugs are exciting breakthroughs but are not without risks. The challenges include tissue-specific targeting and consequently, long-term safety.

Original languageEnglish (US)
Pages (from-to)485-496
Number of pages12
JournalExpert Opinion on Therapeutic Targets
Volume13
Issue number4
DOIs
StatePublished - Apr 2009

Fingerprint

Bone Diseases
Bone
Wnt Signaling Pathway
Bone Regeneration
Bone and Bones
Glycogen Synthase Kinase 3
Anabolic Agents
Adiposity
Neutralizing Antibodies
Osteogenesis
Therapeutics
Animal Models
Safety
Animals
Pharmaceutical Preparations
Modulation
Tissue
Molecules

Keywords

  • Dkk1
  • GSK-3
  • Osteoporosis
  • Sclerostin
  • Sfrp1
  • SOST

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Medicine
  • Drug Discovery
  • Pharmacology

Cite this

Wnt signaling as a therapeutic target for bone diseases. / Hoeppner, Luke H.; Secreto, Frank J.; Westendorf, Jennifer J.

In: Expert Opinion on Therapeutic Targets, Vol. 13, No. 4, 04.2009, p. 485-496.

Research output: Contribution to journalArticle

Hoeppner, Luke H. ; Secreto, Frank J. ; Westendorf, Jennifer J. / Wnt signaling as a therapeutic target for bone diseases. In: Expert Opinion on Therapeutic Targets. 2009 ; Vol. 13, No. 4. pp. 485-496.
@article{9b2aa03c09534c60bd9c92406432a43e,
title = "Wnt signaling as a therapeutic target for bone diseases",
abstract = "Background: There is a need to develop new bone anabolic agents because current bone regeneration regimens have limitations. The Wingless-type MMTV integration site (Wnt) pathway has emerged as a regulator of bone formation and regeneration. Objective: To review the molecular basis for Wnt pathway modulation and discuss strategies that target it and improve bone mass. Methods: Data in peer-reviewed reports and meeting abstracts are discussed. Results/conclusions: Neutralizing inhibitors of Wnt signaling have emerged as promising strategies. Small-molecule inhibitors of glycogen synthase kinase 3? increase bone mass, lower adiposity and reduce fracture risk. Neutralizing antibodies to Dickkopf 1, secreted Frizzled-related protein 1 and sclerostin produce similar outcomes in animal models. These drugs are exciting breakthroughs but are not without risks. The challenges include tissue-specific targeting and consequently, long-term safety.",
keywords = "Dkk1, GSK-3, Osteoporosis, Sclerostin, Sfrp1, SOST",
author = "Hoeppner, {Luke H.} and Secreto, {Frank J.} and Westendorf, {Jennifer J}",
year = "2009",
month = "4",
doi = "10.1517/14728220902841961",
language = "English (US)",
volume = "13",
pages = "485--496",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Wnt signaling as a therapeutic target for bone diseases

AU - Hoeppner, Luke H.

AU - Secreto, Frank J.

AU - Westendorf, Jennifer J

PY - 2009/4

Y1 - 2009/4

N2 - Background: There is a need to develop new bone anabolic agents because current bone regeneration regimens have limitations. The Wingless-type MMTV integration site (Wnt) pathway has emerged as a regulator of bone formation and regeneration. Objective: To review the molecular basis for Wnt pathway modulation and discuss strategies that target it and improve bone mass. Methods: Data in peer-reviewed reports and meeting abstracts are discussed. Results/conclusions: Neutralizing inhibitors of Wnt signaling have emerged as promising strategies. Small-molecule inhibitors of glycogen synthase kinase 3? increase bone mass, lower adiposity and reduce fracture risk. Neutralizing antibodies to Dickkopf 1, secreted Frizzled-related protein 1 and sclerostin produce similar outcomes in animal models. These drugs are exciting breakthroughs but are not without risks. The challenges include tissue-specific targeting and consequently, long-term safety.

AB - Background: There is a need to develop new bone anabolic agents because current bone regeneration regimens have limitations. The Wingless-type MMTV integration site (Wnt) pathway has emerged as a regulator of bone formation and regeneration. Objective: To review the molecular basis for Wnt pathway modulation and discuss strategies that target it and improve bone mass. Methods: Data in peer-reviewed reports and meeting abstracts are discussed. Results/conclusions: Neutralizing inhibitors of Wnt signaling have emerged as promising strategies. Small-molecule inhibitors of glycogen synthase kinase 3? increase bone mass, lower adiposity and reduce fracture risk. Neutralizing antibodies to Dickkopf 1, secreted Frizzled-related protein 1 and sclerostin produce similar outcomes in animal models. These drugs are exciting breakthroughs but are not without risks. The challenges include tissue-specific targeting and consequently, long-term safety.

KW - Dkk1

KW - GSK-3

KW - Osteoporosis

KW - Sclerostin

KW - Sfrp1

KW - SOST

UR - http://www.scopus.com/inward/record.url?scp=67649212001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649212001&partnerID=8YFLogxK

U2 - 10.1517/14728220902841961

DO - 10.1517/14728220902841961

M3 - Article

VL - 13

SP - 485

EP - 496

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 4

ER -